Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    ESGTI

    MCap

    CHF25m

    Last close

    CHF0.97

    ▲ 0.52 (115.56%)

    MagForce

    MCap

    —

    Last close

    -0.02

    ▲ 0.01 (100.00%)

    DFR Gold

    MCap

    CAD15m

    Last close

    CAD0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Executive interview – Basilea Pharmaceutica

Executive interview – Basilea Pharmaceutica

Associated equity: Basilea Pharmaceutica

Basilea Pharmaceutica is focused on treating infectious diseases. Its marketed products are Cresemba (an antifungal) and Zevtera (an anti-MRSA broad-spectrum antibiotic). The company plans to file for US approval for Zevtera.

View this company

Basilea Pharmaceutica — 6 videos in collection

In this video, CEO David Veitch introduces the company, its assets and sets out the key near-term milestones.

< Previous
Next >

You may also be interested in these:

Healthcare

Basilea Pharmaceutica – executive interview

Healthcare

Basilea Pharmaceutica - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free